ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

HHS Carcinogen Guidelines Draft

June 13, 1980

Advisors Ok New RFP For Natural Product Large-Scale Production

March 6, 1992

In Brief: James Cancer Hospial Recieves $20M Donation

January 22, 1999

Sprycell Approved for CML

November 5, 2010

NIH Investigation Clear Gallo Of Charge He Stole Aids Virus

October 12, 1990

Neutron Therapy Contracts Wind Down Next Year; DCT To Consider Whether To Continue Support

March 25, 1988